Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT05650229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05650229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Recruiting
Start date
December 13, 2022
Completion date
November 30, 2027
Enrollment
180 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

primary mitochondrial disease